Recursion Pharmaceuticals Q1 2026 Earnings Narrowed Loss Beats Estimates Amid Pipeline Progress Sera Prognostics Q1 2026 Earnings InLine Loss No Revenue Stock Surges 15 NVNO Q3 2025 Earnings EPS Beat Signals Progress in Cost Management and Clinical Milestones UHS Q1 2026 Earnings Strong EPS Beat Amid Quiet Market Response ERO Q1 2026 Earnings EPS Surges Past Estimates Even as Copper Prices Weigh TSAT Q1 2026 Earnings Significant EPS Miss Amidst Strategic Transition Stock Rises